On August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. Among other things, the IRA imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).
All entries for: Hematology
August 4, 2026
Rigel Pharmaceuticals Inc
Neutral Outlook
South San Francisco, CA
51-200 employees
Recent healthcare reform measures, including the Inflation Reduction Act and changes to government healthcare programs, could adversely affect our business.
Disease Area: Hematology, Multiple, Oncology
Drug Type: Small Molecule
June 10, 2026
Fulcrum Therapeutics
Layoffs
Cambridge, MA
51-200 employees
Just days after announcing it was exploring strategic alternatives for the business after ending development of its lead asset, Fulcrum Therapeutics is cutting 85% of its workforce, according to an SEC filing. The Cambridge, Massachusetts–based biotech will lay off 48 of its 57 employees as part of a restructuring plan approved May 31 meant to significantly reduce operating expenses and preserve capital. Fulcrum informed staff on June 4.
The company announced June 1 it is discontinuing development of pociredir in sickle cell disease, as it no longer sees a viable regulatory path for the drug. Fulcrum noted that the FDA had recently raised concerns regarding pociredir’s benefit-risk profile in that indication.
The biotech expects to mostly complete its layoffs during the second quarter. Fulcrum estimated it will incur about $4.2 million in costs in connection with its restructuring plan, consisting mostly of severance, benefits and related expenses.
Disease Area: Hematology, Multiple, Rare Diseases
Drug Type: Biologic, Small Molecule
May 11, 2026
Sana Biotechnology, Inc.
Negative Outlook
Seattle, Washington
51-200 employees
If we obtain regulatory approval for any of our product candidates, the IRA could substantially and negatively impact the prices we may charge for such products, which could harm our ability to generate revenue and achieve and sustain profitability.
Disease Area: Endocrinology, Hematology, Immune Diseases, Oncology
Drug Type: Biologic
May 7, 2026
Corvus Pharmaceuticals, Inc.
Neutral Outlook
Burlingame, CA
51-200 employees
While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Dermatology, Hematology, Immune Diseases, Oncology
Drug Type: Biologic, Small Molecule
May 6, 2026
GERON CORP
Neutral Outlook
Foster City, CA
51-200 employees
The Inflation Reduction Act of 2022 includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government, including the Medicare Drug Price Negotiation Program, which may ultimately have a negative effect on the pricing for RYTELO… These changes could lower reimbursement for Medicare Part B utilization and require manufacturers to comply with new, uncertain or complex reporting obligations and drug pricing documentation practices.
Disease Area: Hematology, Oncology
Drug Type: Biologic
May 1, 2026
Amgen Inc
Negative Outlook
Thousand Oaks, CA
10,000+ employees
It remains unclear what further policies, legislation and/or actions the Administration, Congress, or state governments will advance with respect to other drug pricing proposals or other healthcare regulations affecting pharmaceuticals, including the MFN EO, IRA and OB3 implementation, trade policies, or state laws affecting the 340B Program or Medicaid reimbursement that could ultimately be adopted more broadly. To the extent such actions reduce or modify coverage or reimbursement for our products, increase rebates or other costs, constrain pricing decisions, or otherwise limit product use, they would have an adverse effect on our business and results of operations.
Disease Area: Cardiovascular, Hematology, Metabolic Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule